Социально-экономическая доступность антинеопластических лекарственных средств в Украине

Abstract

The results of evaluation of social and economic availability of antineoplastic drugs for the average Ukrainian patient are highlighted. Indicator of the adequacy of solvency (Ca.s.), which shows the share of the average wage of Ukrainian patients needed for the purchase of a package of a drug, was used. The analysis showed, that the majority of antineoplastic drugs (58%) were less available for the average citizen of Ukraine. The largest share of highly available trade names with Ca.s.<5% were in two pharmacological groups: antimetabolites (share of drugs with Ca.s.<5% - 26%) and cytotoxic antibiotics (share of drugs with Ca.s.<5% - 20%), which were widely represented by generic drugs. The most unavailable drugs (Ca.s.>15%) were the plant alkaloids and other antineoplastic drugs of natural origin (share of drugs with Ca.s.> 15% - 73%) and alkylating agents (share of drugs with Ca.s.>15% - 58.3%). Majority of these drugs were drugs of new generation: sorafenib (Ca.s.=926), regorafenib (Ca.s.=1342), cabazitaxel (Ca.s.=1474), which were represented by the original trade names in the pharmaceutical Ukrainian market. Low socio-economic availability for Ukrainian patients of majority of antineoplastic agents causes neces-sity the development of the government program of complete or partial reimburse-ment of antitumor therapy cost.